- Journal Details
- Format
- Journal
- First Published
- 31 Dec 2013
- Publication timeframe
- 4 times per year
- Languages
- English
This article reviews the application of contrast-enhanced ultrasound (CEUS) in gauging renal microvascular perfusion in diverse renal diseases. The unique nature of the contrast agents used in CEUS provides real-time and quantitative imaging of the vasculature. In addition to the traditional use of CEUS for evaluation of kidney masses, it also emerges as a safe and effective imaging approach to assess microvascular perfusion in diffuse renal lesions, non-invasively. Although the precise CEUS parameters that may best predict disease still warrant systematic evaluation, animal models and limited clinical trials in humans raise hopes that CEUS could outcompete competing modalities as a first-line tool for assessing renal perfusion non-invasively, even in ailments such as acute kidney injury and chronic kidney disease.
Key words
- ultrasound
- microvascular perfusion
- acute kidney injury
- chronic kidney disease
- imaging
- glomerular filtration rate
- computed tomography
- magnetic resonance imaging
Cumulative evidence indicates that renal hemodynamic changes underlie several kidney diseases with diffuse lesions[1,2]. Hyperperfusion has been documented in progressive glomerular injury, especially in diabetic kidney disease (DKD)[1]; renal blood flow (RBF) has been found to be changed in septic acute kidney injury (AKI) [2,3]; renal dysfunction has also been associated with a significant change in cortical perfusion [4]. Contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) have been used to measure RBF and glomerular filtration rate [5]. However, CT and dynamic MRI techniques for measuring blood perfusion often depend on intravenous injection of contrast agents [6,7], which are potential hazards in patients with renal insufficiency [8]. Although functional MRI can be performed without contrast agents, the invasive nature of the pharmacological or physiological manipulations associated with this approach[9], and the lack of standardized sequences, post-processing software and models hinder its routine application in the clinic [10].
Contrast-enhanced ultrasound (CEUS) is a competing technology that enables realtime observation of vascular perfusion. The basic composition of the contrast agents are microbubbles made of gases embedded within a shell, which can function as red blood cell tracers. Their ability to reflect ultrasound and avoid destruction during circulation allows for continuous imaging of the vasculature and blood flow[11]. These contrast agents are well-regarded for their renal safety, high tolerance, and lack of radiation [12]. Hence, CEUS is widely used for the diagnosis of various kidney masses, such as tumors, cystic lesions, infarction, cortical necrosis, and trauma-induced lesions, among others.
However, it is now becoming evident that changes in renal perfusion may also help predict and monitor the progression of other renal diseases. CEUS can provide
real-time, noninvasive and relative quantitative estimates of renal microvascular perfusion independent of kidney function. This review will focus on the potential applications of CEUS in monitoring renal microvascular perfusion in various kidney diseases.
European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) Guidelines and Recommendations, updated in 2011, had documented the potential indications of CEUS in kidney diseases [13]. Besides their echogenicity, renal tumors exhibit altered vascularity compared to the normal parenchyma, and CEUS can be helpful in their differential diagnosis [14]. For detection of cyst-like lesions, CEUS is even more sensitive than contrast-enhanced CT [15]. Owing to the excellent spatial resolution of CEUS, cortical necrosis is shown as a non-enhancing area with vascularity. CEUS is also superior to color Doppler ultrasound in diagnosing renal infarction, because CEUS can detect slower flow in smaller blood vessels. Kidney abscesses can also be confirmed and followed up using CEUS [16]. Since contrast agents are not concentrated in the collecting system, CEUS assessment of kidney trauma cannot rule out pelvi-calyceal and ureteric injuries; therefore, CEUS may be better suited for limited injuries, or multiple solid organ traumas [17].
The application of CEUS for studying renal microvascular perfusion has been examined in many animal models. Histological assessment in porcine models have shown that the ultrasound contrast agent used (sulfur hexafluoride) did not inflict any tissue damage to the kidneys [18]. These findings suggest that CEUS could be safe for regular use in humans, with minimal risk of tissue damage. Kogan
CEUS-based renal perfusion parameters have been documented in healthy animals. Time-dependent intensity curves can readily be generated based on selected regions of interest (ROI) in the renal cortex and medulla, as exemplified in Figure 1. Peak intensity (PI), time to peak intensity (TTP), mean transit time (MTT), and area under the curve (AUC) are some of the key observational parameters that are typically used in renal perfusion studies, as illustrated in Figure 1. Different animals exhibited similar renal perfusion enhancement patterns under CEUS: the renal cortex enhanced initially followed by medullary enhancement [20-23]. Moreover, another study revealed that the location and size of ROIs used for this imaging approach did not make significant differences to the renal perfusion metrics captured using CEUS [21]. This result augurs well for the routine analysis of CEUS data based on ROIs in clinical practice.
Contrast-enhanced ultrasound parameters derived from the perfusion model. These parameters include peak intensity (PI, with respect to PI of the reference ROI), rise time (RT), time to peak (TTP), and mean transit time (MTT). AUC (area under curve) is divided into two parts, which includes AUC1 (area under ascending curve) and AUC2 (area under descending curve)
CEUS has also been used for renal perfusion evaluation in pathological conditions. In diabetic Goto-Kakizaki rats, renal perfusion, as estimated by CEUS, consistently matched the pathological changes in the kidneys [24]. When compared to normal controls, dogs with iatrogenic hypercortisolism had significantly increased CEUS PI and AUC values in their kidneys compared to controls [25]. CEUS has also been successfully used for monitoring renal microvascular perfusion in ischemia/reperfusion injury in mice [26], chronic renal ischemic injury in animal models[27], porcine intra-abdominal hypertension [28], as well as global hypoxia in piglets [29]. Examination of norepinephrinetreated dogs showed that CEUS parameters were predictive of effective renal plasma flow, suggesting that CEUS could also be used in assessing renal perfusion following pharmacologic intervention [30].
Collectively, these studies in diverse animal models reveal that CEUS could be used for the non-invasive evaluation of renal microvascular perfusion under different disease settings. These animal studies have laid the foundation for further systematic evaluation of CEUS in human renal diatheses.
Measurement of RBF in a clinical setting is highly challenging. Current methods include utilizing para-aminohippurate (PAH) or a radioisotope tracer. Although PAH still remains a gold standard, the technical difficulties associated with its use have limited its routine application in the clinic, although it is commonly used for research. Nuclear medicine based techniques also pose problems such as requiring time for excretion of the injected radioisotopes out of the body, and concerns regarding radioisotope exposure. Against this backdrop, CEUS offers a novel approach for RBF evaluation, without the above-mentioned concerns, as it appears to be fast, noninvasive, and safe. Observations in healthy volunteers reveal that CEUS-ascertained parameters exhibit good correlation with findings obtained using PAH [31]. CEUS has also been used to evaluate renal microvascular perfusion following the administration of vasoactive drugs. CEUS ascertained parameters decreased after the use of angiotensin II (Ang II), and increased after captopril (Ang II inhibitor) administration[32]. Noradrenaline- [33] and dopamineinduced [34] changes in renal perfusion were also correctly validated by CEUS. Another CEUS-based study [35] showed that diclofenac sodium decreased renal perfusion, but etodolac did not. Collectively, these studies justify the use of CEUS for monitoring the impact of novel drugs on renal perfusion.
In humans, CEUS has already been applied to the study of various kidney diseases, including chronic kidney disease (CKD) [36] (notably DKD [1,37]), AKI [38], and kidney transplantation [39]. All of these investigations indicate that CEUS is well-tolerated, and that the subjects experience no side effects due to the contrast agents.
Studies document that CEUS could reflect renal perfusion in real-time in AKI [40], and could predict acute rejection [41] and delayed graft function [42] in kidney transplantation. With progression of CKD stages, CEUS-ascertained renal enhancement showed delayed increase and decrease of PI, and acceleration of decay [43]. Quantitative analysis established that early stages of CKD (stages 1 and 2) were marked by decreased AUC compared to healthy controls [36]. Similar results were also reported in DKD [1,44]. By evaluating renal microvascular perfusion, CEUS could not only estimate renal dysfunction, but also could predict early kidney injury. Urinary microalbumin/creatinine (MALB/ UCR) is a well-known early biomarker for DKD, and its levels could increase before renal dysfunction. Ling
The limitations of using CEUS to assess renal microvascular perfusion include the following. First, there is no international standard for evaluating renal microvascular perfusion; well-powered clinical trials are still needed to establish the parameters that are optimal for clinical evaluation and the normal range in different subjects groups. Second, the logistics associated with CEUS need to be factored in. Additional time may be needed for placing an intravenous catheter and quantitative analysis, while the cost of agents should also be considered. Third, patients with serious cardiac problems and pulmonary disease cannot be subjected to CEUS. However, this limitation may be less frequent than the contraindication for contrast enhanced computed tomography (CT) or magnetic resonance (MR) relating to patients’ anaphylactic history or renal status. Finally, contrast agents used in CEUS are not excreted into the collecting system; thus, the latter will not be adequately imaged.
Representative serial contrast-enhanced images in early stage of diabetic kidney disease (DKD) patients with different levels of urinary microalbumin/creatinine ratio (MALB/UCR). Early stage of DKD is defined as DKD patients with estimated glomerular filtration rate ≥90 mL/min/1.73m2 (chronic kidney disease stage 1). All subjects went through the same enhance and fading stages. Early stage of DKD patients with MALB/UCR≥10 g/mol got a higher peak intensity and increased time for
Despite these limitations, CEUS is still a promising method for renal microvascular evaluation. Well-designed and large-scaled clinic trials that systematically evaluate the predictive power of CEUS in various settings of AKI and CKD are clearly needed. Looking to the future, it is exciting to note that the technology used for CEUS can potentially lend itself to ultrasound-directed therapeutic delivery systems using microbubbles. Given its diagnostic and potential therapeutic potential, CEUS appears likely to grow in prominence over the coming decade.
Chronic stress-induced immune dysregulation in breast cancer: Implications of psychosocial factors MiR-182/Sestrin2 affects the function of asthmatic airway smooth muscle cells by the AMPK/mTOR pathway Retinal examination modalities in the early detection of Alzheimer's disease: Seeing brain through the eye TCDD-inducible poly (ADP-ribose) polymerase promotes adipogenesis of both brown and white preadipocytes The long and the short of current nanomedicines for treating Alzheimer's disease Long-term blood pressure outcomes of laparoscopic adrenalectomy in trHTN patients